Heterobivalent Radioligands Improve Tumor Volume Control in Fibroblast-Activation Protein α (FAP) Positive Tumours (EANM 2026) - Sep 29, 2026 - Abstract #OP-725; Pres time: Oct 20, 2026; 04:45 PM - 06:15 PM; Location: Hall E2; "Several strategies have been explored to overcome this limitation, including multimerisation of FAPI scaffolds to improve tumour retention4, and the use of cyclic peptides such as FAP-2286, exhibiting prolonged FAP engagement5... The heterobivalent [177Lu]Lu-FAP-6s.HB outperformed the homodimeric [177Lu]Lu-FAP-6s.D in a preclinical therapeutic setting, achieving greater tumour growth retardation whilst maintaining a favourable tolerability profile. These results support the heterobivalent strategy as a promising approach to enhance the therapeutic efficacy of FAP-targeted radioligand therapy."
Oncology • Solid Tumor • FAP
|
|
T. Bailly; J. Millul; M. Fani
|